Imatinib (also known as “Gleevec” or “Glivec”), a tyrosine kinase inhibitor, was called as “magical bullet,” when it revolutionized the treatment of CML in 2001. Imatinib was invented in the late 1990s by biochemist Nicholas Lyndon then working for Ciba–Geigy (now Novartis), and its use to treat CML was driven by Brian Druker, an oncologist at the Dana–Farber Institute. The first clinical trial of Imatinib took place in 1998 and the drug received FDA approval in May 2001. Lyndon, Druker, and the other colleagues were awarded the Lasker–DeBakey Clinical Medical Research Award in 2009 for “converting a fatal cancer into a manageable condition” and the Japan Prize in 2012 for their part in “the development of a new therapeutic drug targeting cancer–specific molecules.”